Table 1. Pharmacokinetics of OxPt plus IRI and OxPt/SN38 on Sprague–Dawley Ratsa.
| drug | analyte | t1/2 (h) | Cmax (μM) | AUC0-inf (μM h) |
|---|---|---|---|---|
| OxPt | Pt | 0.90 ± 0.32 | 25.80 ± 2.98 | 140.54 ± 42.34 |
| irinotecan | irinotecan | 2.71 ± 1.82 | 1.34 ± 0.37 | 9.29 ± 3.60 |
| SN38 | 1.87 ± 1.34 | 0.61 ± 0.02 | 1.30 ± 0.53 | |
| OxPt/SN38 | Pt | 30.84 ± 4.95 | 93.13 ± 16.15 | 2946.28 ± 1062.03 |
| Chol-SN38 | 9.74 ± 0.99 | 170.53 ± 14.10 | 1211.76 ± 26.19 | |
| SN38-TMS | 4.03 ± 1.19 | 6.59 ± 2.14 | 25.99 ± 4.92 | |
| SN38 | 4.22 ± 1.28 | 0.02 ± 0.01 | 0.15 ± 0.04 |
a
PK was performed by a single intravenous injection of OxPt plus irinotecan or OxPt/SN38 at 2.0 mg/kg OxPt and 3.6 mg/kg SN38 equiv with noncompartmental analysis.